Grifols Egypt donation centers receive first international plasma industry quality certification outside North America and Europe

Barcelona, Spain, July 31, 2023 - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world’s leading producers of plasma-derived medicines with a more than 110-year track record of contributing to the health and well-being of people around the world, has announced that its first donation centers in Egypt have been certified by the plasma industry’s recognized authority on international quality and safety criteria, the only ones outside North America and Europe to receive this distinction.

Validation from the Plasma Protein Therapeutics Association’s (PPTA) International Quality Plasma Program (IQPP), which confirms best industry practices through third-party audits, formalizes the high standards already followed by Grifols Egypt.

IQPP’s certification now covers Grifols Egypt’s first donation centers and is expected to eventually include all 20 locations that will be opened by the end of 2024. The recognition considers all key processes governing donor health and the quality of donor center operations to ensure the highest levels of excellence for the plasma used to make patient treatments.

Having its first donor centers certified is another defining moment for Grifols Egypt, which is moving steadily toward its goal of completing the world’s only fully integrated plasma-supply platform, a showcase for plasma self-sufficiency in which plasma from Egyptians is manufactured into medicines in Egypt, used to treat Egyptian patients and strengthen the country’s healthcare system.

Soon hospitals in Egypt will receive delivery of the very first Grifols Egypt medicines, large quantities of albumin, used in major surgery and to treat trauma and burns. This begins a continuous stream of other lifesaving therapeutics that will also include immunoglobulins (Ig) for immunodeficiencies and blood-clotting factors to manage bleeding disorders. For the time being the treatments are being manufactured at Grifols’ plant in Parets del Vallès (Barcelona) until the Grifols Egypt production facilities going up in the New Administrative Capital’s medical city, along with testing and warehouse operations, are completed and operational.

“Grifols is proud of its IQPP certification in Egypt, another big step in establishing a game-changing integrated plasma collection and manufacturing infrastructure that will benefit patients in the country and entire region,” said Raimon Grifols, Grifols Chief Corporate Officer.

“Recognition that our donor centers follow the highest and most demanding international operating norms is in line with Egypt’s commitment to becoming a plasma and healthcare leader in the Middle East and Africa,” said Dr. Magdy Amin, CEO Grifols Egypt.

Added Anita Brikman, PPTA President and CEO: “The PPTA notes that this is the first time that IQPP standards have been implemented in Africa, demonstrating the global importance of the industry’s voluntary commitment to standards that go beyond regulatory requirements. PPTA is proud to welcome Grifols Egypt plasma donation centers to the IQPP family.”

As demand for plasma medicines continues to grow, countries and regions are looking to ensure sustainable supplies. Through its Global Plasma Self-sufficiency Program, Grifols is spearheading innovative public-private alliances to help achieve strategic autonomy in essential plasma therapies. In addition to its partnership with the Egyptian government, Grifols has a long-term agreement with Canadian Blood Services, Canada’s national blood authority, to greatly increase the country’s self-sufficiency in Ig medicines through an all-Canadian collection and manufacturing infrastructure.